Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants

Nat Cancer. 2023 Sep;4(9):1220-1221. doi: 10.1038/s43018-023-00631-x.

PMID: 37743367 DOI: 10.1038/s43018-023-00631-x

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-132846

Vepafestinib

98.61%, RET Inhibitor

RET; Apoptosis

Cancer

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator; DNA/RNA sequence conversion tools

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2025 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us